Market Signal Briefing

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members – current and proposed – are committed to accelerating the growth of the company Allschwil, Switzerland – March 24, 2026
Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia Misciattelli, Chief Executive Officer and member of the Board of Directors at AAVantgarde Bio; Gabriel Baertschi, Chief Executive Officer of Grünenthal; and André C. Muller, former Chief Executive Officer of Idorsia.

Natalia Misciattelli and Gabriel Baertschi are nominated as independent members of the Board. Having served as Chief Executive Officer of Idorsia until June 2025 and currently acting as an advisor to the Board, André Muller is nominated as a non-independent member.

The proposed composition further strengthens the Board with senior leaders who bring deep experience in global operations, biopharmaceutical innovation, commercial execution, and long-term strategic execution, while ensuring continuity through extensive company knowledge.

Mathieu Simon, Vice Chairman and Lead Independent Board member, commented:
“We are very pleased to nominate Gabriel Baertschi, Natalia Misciattelli, and André C. Muller for election to Idorsia’s Board of Directors. Gabriel and Natalia bring broad, complementary expertise from across the biopharmaceutical and biotech sectors, while André’s deep knowledge of Idorsia will help ensure continuity as the company moves forward. Together, their experience will strengthen the Board’s ability to support the company to accelerate commercial performance, business development opportunities, and the innovative pipeline.”

Biographies of the nominees
Natalia Misciattelli (Independent candidate)
Dr Natalia Misciattelli is the Chief Executive Officer and a member of the Board of Directors at AAVantgarde Bio, a biotechnology company developing next‑generation gene therapies. She brings more than 25 years of international executive experience spanning from advancement of novel therapeutic platforms, operational transformation, corporate development & capital strategy.

Her extensive experience combined with her leadership across multiple innovative biotech environments – will provide valuable insight as Idorsia advances its pipeline and growth priorities.

Gabriel Baertschi (Independent candidate)
Gabriel Baertschi currently serves as Chief Executive Officer of Grünenthal, a global leader in pain research and management. With more than 20 years of international pharmaceutical experience, he has held senior leadership roles across Europe, Asia, and in global therapeutic area strategic roles, consistently delivering portfolio expansion, operational excellence, and organizational transformation.
His proven track record in commercial strategy, market expansion, M&A, and patient-focused innovation will support Idorsia’s commitment to sustainable long-term value creation.

André C. Muller (Non‑Independent candidate)
André C. Muller previously served as Chief Executive Officer of Idorsia, having joined the company at its creation in 2017 as Chief Financial Officer. He played a central role in Idorsia’s development, transformation initiatives, and business development strategy over several years, and continues to advise the organization.

His nomination as a non‑independent Board member reflects the Board’s confidence in the value of his deep understanding of Idorsia’s business, assets, and strategic trajectory. Mr Muller brings extensive leadership experience across pharmaceutical R&D strategy, finance, and long‑term business planning.

Re‑election of Board members
The Board will also propose the re-election of Jean-Paul Clozel (who will also stand for the role of Chairman), as well as the re-election of independent Board members Mathieu Simon (Vice-Chairman and Lead Independent), and Sandy Mahatme.

Bart Filius has informed the Board that he will not stand for re-election at the AGM 2026.

Jean-Paul Clozel, MD, Chairman of the Board of Idorsia, commented:
“I’m very pleased that Mathieu and Sandy will stand for re-election, bringing continuity to the Board. I would also like to extend my gratitude to Bart. He has been a consummate professional throughout his tenure, supporting the company during an important period in Idorsia’s evolution. He has always supported our common vision of improving the life of patients with innovative R&D and shown great enthusiasm for our pipeline.”

Annual General Meeting 2026
The AGM to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026.

The company encourages all shareholders to register their shares no later than 17:00 CEST on April 27, 2026, in order to vote at the AGM either in person or through the independent proxy card, which will be distributed in due course.

Notes to the editor

About Natalia Misciattelli
Dr Misciattelli has been Chief Executive Officer and a member of the Board of Directors at AAVantgarde Bio since 2022. Prior to joining AAVantgarde, she served as Chief Business Officer at NovalGen and Senior Vice President of Strategy & Operations at Freeline. Her earlier career includes roles at Arthur Andersen in London, corporate development at GE Healthcare, and partnership leadership at PA Consulting, advising global clients across Europe, the United States, Asia, and Latin America.

Nationality: Danish
Year of birth: 1972
Education: B.Sc. and Ph.D. in Microbiology, Bangor University, University of Wales, UK
Board membership: Fishmonger Livery Company (non-listed)

About Gabriel Baertschi
Gabriel Baertschi has served as Chief Executive Officer and Chairman of the Corporate Executive Board of Grünenthal since 2016. He previously held senior international leadership roles at AstraZeneca, including Company President for Japan, Germany, and Thailand, and General Manager for Vietnam and Indonesia.

Nationality: Swiss
Year of birth: 1974
Education: Master of Science in Biology, University of Neuchâtel; “Leading Enterprise Transformation” program, Harvard Business School
Board membership: DKSH Holding AG (listed), MedXCell (non-listed)

About André Muller
André C. Muller joined Idorsia at its creation in June 2017 as Chief Financial Officer, having previously served as CFO of Actelion since 2013. He became Idorsia’s Chief Executive Officer in June 2024 following the retirement of founder and CEO Jean‑Paul Clozel, serving for one year before transitioning to an advisory role. Before Actelion, he held senior financial leadership positions at Pierre Fabre SA.

Nationality: French
Year of birth: 1963
Education: Master’s degree in Business Administration, EMLYON Business School, Lyon, France
Board membership: Cellectis (listed), Chiron Investments AG (non‑listed)

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected] – [email protected] – www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Press Release PDF

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo

BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions

BP is the seventh approved indication for Dupixent in Japan

TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP).

The approval in Japan is based on data from the pivotal LIBERTY-BP-ADEPT Phase 2/3 trial, which evaluated Dupixent in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. For the primary endpoint, more than four times as many patients on Dupixent experienced sustained disease remission compared to placebo (18% vs. 4%; p=0.0250) at Week 36 in the companies’ core dataset used for the regulatory submission in Japan.

Treatment-related adverse events (AEs) occurred in 26% of Dupixent patients and 15% of placebo patients. The treatment-related AE most commonly reported with Dupixent was conjunctivitis (4%).

In addition to BP, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD).

About BP
BP is a rare skin disease that primarily affects elderly patients, and is characterized by intense itch, painful blisters and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient’s immune system.

About ADEPT
ADEPT was a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP for a 52-week treatment period. After randomization, patients received Dupixent or placebo every two weeks after an initial loading dose, along with OCS treatment. During treatment, OCS taper was initiated after patients experienced two weeks of sustained control of disease activity. OCS tapering could start between four to six weeks after randomization and was continued if disease control was maintained, with the intent of completion by Week 16. After OCS tapering, patients were only treated with Dupixent or placebo for the rest of the trial (rescue treatment could be used if required).

The primary endpoint evaluated the proportion of patients achieving sustained disease remission at Week 36. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by Week 16 without relapse after completion of the OCS taper and no rescue therapy use during the 36-week treatment period. Relapse was defined as appearance of ≥3 new lesions a month or ≥1 large lesion or urticarial plaque (>10 cm in diameter) that did not heal within a week. Rescue therapy could include treatment with high-potency topical corticosteroids, OCS (including increase of OCS dose during the taper or re-initiation of OCS after completion of the OCS taper) or systemic non-steroidal immunosuppressive medications or immunomodulating biologics.

About Dupixent
Dupixent is now available in Japan as a 300 mg pre-filled syringe or pre-filled pen for adults with bullous pemphigoid. Dupixent is intended for injection under the skin (subcutaneous injection) and is given every two weeks after an initial loading dose. It can be given in a clinic or at home by self-administration after training by a healthcare professional.

Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, CSU, COPD, BP and allergic fungal rhinosinusitis (AFRS) in different age populations. More than 1,400,000 patients are being treated with Dupixent globally.1

About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, Board co-Chair, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

Dupilumab Development Program
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 12,000 patients with various chronic diseases driven in part by type 2 inflammation. 

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. 

U.S. INDICATIONS

DUPIXENT is a prescription medicine used:

to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age.to treat adults and children 6 years of age and older with allergic fungal rhinosinusitis (AFRS), who have had surgery on their nose or sinuses in the past. It is not known if DUPIXENT is safe and effective in children with AFRS under 6 years of age. DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

have eye problems.have a parasitic (helminth) infection.are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, BP, or AFRS and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms. The most common side effects include:

Eczema: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).Prurigo Nodularis: eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.Chronic Spontaneous Urticaria: injection site reactions.Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections.Allergic Fungal Rhinosinusitis: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.  

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. 

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of adults with bullous pemphigoid; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Sanofi Disclaimers or Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.

Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements.

Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Regeneron Contacts: 
Media Relations 
Kailey Kilmartin
Tel: +1 914-652-0679
[email protected]
Investor Relations 
Mark Hudson
Tel: +1 914-847-3482 
[email protected]
  Sanofi Contacts: 
Media Relations 
Sandrine Guendoul
Tel: +33 6 25 09 14 25
[email protected]
Investor Relations 
Thomas Kudsk Larsen
Tel: +44 7545 513 693
[email protected]
  Evan Berland 
Tel: +1 215-432-0234
[email protected]
Alizé Kaisserian
Tel: +33 6 47 04 12 11
[email protected]
  Léo Le Bourhis
Tel: + 33 6 75 06 43 81
[email protected]
Keita Browne
Tel: +1 781-249-1766
[email protected]
  Victor Rouault  
Tel: +1 617 356 4751
[email protected] 
Nathalie Pham 
Tel: +33 7 85 93 30 17 
[email protected]
  Timothy Gilbert 
Tel: +1 516-521-2929
[email protected]
Nina Goworek
Tel: +1 908 569 7086
[email protected]
  Léa Ubaldi
Tel: + 33 6 30 19 66 46
[email protected]
Thibaud Châtelet 
Tel: +33 6 80 80 89 90 
[email protected]
  Ekaterina Pesheva
Tel: +1 410 926 6780
[email protected] Li 
Tel: +33 6 84 00 90 72 
[email protected]   1 Data on File

The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident and critical treatment decisions that are vital for high-risk patients. Designed for the cobas eplex system, the test is easy to use and available around the clock, helping hospitals manage surges in respiratory cases. , /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spectrum of viruses and bacteria that cause respiratory illness. The test is now available in countries accepting the CE mark.

Differential diagnosis of respiratory infections can be complex because many of the viruses and bacteria associated with respiratory infections may cause very similar symptoms. For vulnerable populations, including the elderly, young children, and those with weakened immune systems, a respiratory infection can quickly become life-threatening.

"In respiratory care, time is everything. Knowing exactly what is making a patient sick allows clinicians to make fast, effective decisions that can save lives," said Josh Lauer, Global Head of Molecular Labs at Roche Diagnostics. "We are providing hospitals with a powerful tool to manage the complexity of respiratory infections, ensuring that patients — especially those at high risk — get the targeted care they need without delay."

The cobas eplex RP3 panel provides critical support to healthcare providers during peak respiratory seasons, which are the most demanding times of the year. The new test detects more than 20 different viral and bacterial pathogens simultaneously. This helps clinicians quickly pinpoint the exact cause of a patient's illness, allowing them to start the right treatment sooner, implement adequate infection and transmission control measures, and, in some cases, avoid unnecessary antibiotic use and improve patient prognosis.

With less than one minute of hands-on time required to start the test, it is incredibly easy for laboratory staff to use. With ease of use and fast time to results, the cobas eplex RP3 panel can help reduce the time patients spend in the emergency room and allows hospitals to better manage isolation beds, keeping infectious patients separate from others.

About the cobas eplex RP3 Panel
The cobas eplex respiratory pathogen panel 3 is a qualitative in vitro diagnostic test aimed at the simultaneous detection and differentiation of up to 25 viral and bacterial targets. It runs on the cobas eplex system, a platform designed to simplify laboratory workflow with features like automated result reporting and external control tracking & monitoring. Like the RP2 panel, the RP3 panel detects common pathogens, such as influenza virus A and B, RSV, SARS-CoV-2,, plus new pathogens including Bordetella parapertussis and Chlamydia pneumoniae that can cause severe illness in high risk patients. The cobas eplex RP3 panel also has updated inclusivity for influenza virus and SARS-CoV-2 to ensure coverage of current and recently circulating strains. This test is also the first in the cobas eplex family to feature flexible syndromic testing, giving the option to labs to customise up to 5 distinct panels based on local prevalence needs or unique patient presentations.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information please contact

Yvette Petillon, Group Media Relations
Phone: +41 79 961 92 50
e-Mail: [email protected]

Brien Mahoney, Molecular Labs Communications
Phone: +1 925 699 8512
e-Mail: [email protected]

SOURCE Roche

13.35K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Aquestive class action, go to https://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose the true state of Aquestive's New Drug Application ("NDA") for Anaphylm; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Aquestive class action, go to https://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289671

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BlackRock TCP Capital Corp. (NASDAQ: TCPC) between November 6, 2024, and January 23, 2026, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased BlackRock TCP securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BlackRock TCP class action, go to https://rosenlegal.com/submit-form/?case_id=52921 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about BlackRock TCP’s business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) BlackRock TCP’s investments were not being timely and/or appropriately valued; (2) BlackRock TCP’s efforts at portfolio restructuring were not effectively resolving challenged credits or improving the quality of the portfolio; (3) as a result, BlackRock TCP’s unrealized losses were understated; (4) as a result, BlackRock TCP’s net asset value was overstated; and (5) as a result of the foregoing, defendants’ positive statements about BlackRock TCP’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the BlackRock TCP class action, go to https://rosenlegal.com/submit-form/?case_id=52921 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of  securities of Concorde International Group Ltd. (NASDAQ: CIGL) between April 21, 2025 and July 14, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2026.

SO WHAT: If you purchased Concorde securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Concorde class action, go to https://rosenlegal.com/submit-form/?case_id=56776 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Concorde was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Concorde’s public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants’ positive statements about Concorde’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Concorde class action, go to https://rosenlegal.com/submit-form/?case_id=56776 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Alibaba group logo is seen in this illustration taken, February 11, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

BEIJING, March 24 (Reuters) - Alibaba (9988.HK), opens new tab on Tuesday revealed its next-generation XuanTie C950 5-nanometer processor at an internal conference on Tuesday, local ​media reported, as the Chinese tech giant gears up ‌for the shift towards agentic AI.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

The 3.2 GHz server chip, built using open-source RISC-V chip architecture, was billed as "the highest performing RISC-V CPU ​in the world" at a conference hosted by DAMO ​Academy, Alibaba's research arm, according to the reports.

The chip ⁠performs more than three times faster than its predecessor, ​the XuanTie C920, the reports said.

The company did not reveal which ​fab manufactured the chip.

Alibaba did not immediately respond to an emailed request for comment.

Alibaba is accelerating in-house chip development through its T-Head semiconductor ​arm, primarily focusing on the Zhenwu 810E chip series for ​AI training and inference, while the XuanTie series is focused on high-performance ‌cloud ⁠systems and agentic AI.

The move comes after Alibaba last week launched Wukong, its enterprise platform optimised for AI agent workflows, as companies and institutions throughout China adopt OpenClaw.

Its international equivalent, Accio Work, ​was launched on ​Monday. The agentic ⁠AI platform says it can autonomously run complex business operations for small and medium-sized enterprises.

The ​firm reorganised some of its AI-focused teams under ​the ⁠newly created Alibaba Token Hub earlier this month, which focuses on building AI work platforms for enterprises.

The business strategy shift comes ⁠as ​Alibaba finds new ways to ensure ​profitability as Chinese AI models' token prices have dropped dramatically amid fierce domestic ​competition.

Reporting by Laurie Chen and Che Pan; Editing by Kevin Buckland

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Target (TGT +1.47%) has been one of the biggest flops in the retail sector since the pandemic ended.

Over the last five years, the stock is down 30%, and is off more than 50% from its all-time peak around the same time.

The company has struggled with theft, inflation, stiff competition from Walmart, Costco, and Amazon, a shifting political stance that has alienated its customers, and a deteriorating in-store experience that have contributed to a decline in comparable store sales.

Now, a new CEO has breathed new life into Target stock and investors see an opportunity for a turnaround. In a year when the S&P 500 is down, Target is up 18% year-to-date through March 23, largely because new CEO Michael Fiddelke has instilled a sense of confidence in the company's turnaround potential, even after middling fourth-quarter results earlier this month.

Fiddelke hasn't wasted any time in rolling out new ideas to recover lost business, and a key test for the company is coming this week: Target's Circle Deal Days.

Image source: Target.

What is Target Circle Deal Days? Target's Circle Deal Days is a three shopping promotion from March 25-27, seemingly designed to compete with Amazon's Big Spring sale, to promote Target Circle, its free loyalty program, and a Target Circle 360 membership program that offers similar benefits to Amazon Prime.

Target Circle Deal Days offers 40% off or more on a wide range of items, and members who join Target Circle will get 15% off on one shopping trip. The focus on loyalty is part of a larger strategy under Fiddelke, which includes experiential benefits and rewards in specific categories like beauty or Starbucks.

Circle Deal Days also gives the retail stock a chance to draw customers to its store, at a time when it wants to show customers that it's spruced up its stores with a refreshed product lineup, renewed commitment to customer service, and revamped store layouts.

Fiddelke's top objective should be returning the business to comparable sales growth, and Circle Deal Days gives it a good opportunity to do so. Not only should the event itself drive increased sales, but it also gives Target a chance to boost its loyalty membership, including Target 360, to show off its stores, and convince customers it's lost to start shopping there more.

Target's comps have been down for the last four quarters and 11 of the last 13 quarters. That's an awful track record for any retailer and shows that there's more than one problem weighing on Target's performance. However, it also gives Fiddelke a low bar to grow the business from. Target can win back those customers, and the plan to revamp the in-store experience, improve loyalty, and drive ancillary revenue streams is clear.

Today's Change

(

1.47

%) $

1.67

Current Price

$

114.93

Is Target a buy? I've been a shareholder of Target for several years now, patiently waiting out the post-pandemic malaise.

The retailer has a lot of things going for it. It occupies a unique space among multi-category retailers with its cheap chic reputation, and it serves urban, suburban, and rural markets well, something that peers like Walmart have struggled with.

However, Target has clearly faltered in recent years due to what appears to be a combination of mismanagement, tougher competition, and a challenging macroeconomic environment.

Target now trades at a price-to-earnings ratio of just 14, which is much cheaper than peers like Walmart, and it offers a dividend yield of 4%.

That's an attractive valuation and yield, but I'd like to see a clearer sign that Target's turnaround efforts are paying off. Fiddelke is saying the right things, but Target has disappointed investors enough times in the last few years that they should know not to get ahead of themselves with hopes of a recovery.

Target offered modest guidance, calling for just 2% net sales grow this year. If the company raises that guidance, that would be a clear buy signal from management, showing that the turnaround is indeed paying off.

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), of the important April 21, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Corcept class action, go to https://rosenlegal.com/submit-form/?case_id=51868 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, defendants repeatedly told investors that “relacorilant is approaching approval.” In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Corcept class action, go to https://rosenlegal.com/submit-form/?case_id=51868 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Nvidia (NVDA +1.80%) CEO Jensen Huang said at GTC 2026 that there is roughly $1 trillion of cumulative demand for Nvidia's Blackwell and Rubin chips through 2027. That's a big jump from the $500 billion worth of demand he shared a year ago.

That comment arguably matters more for investors today than it did back then. Valuations across several artificial intelligence (AI) infrastructure leaders have come down in recent months, yet Huang's message is that AI demand remains strong.

Nvidia is the obvious beneficiary. But Huang also called out Dell Technologies (DELL +4.50%) and Amazon (AMZN +2.33%) in his keynote. Here's why all three could be smart buys right now.

Image source: Getty Images.

Nvidia: The AI chip leader Huang's insight into purchase orders from top AI companies, researchers, and sovereign nations, all customers of Nvidia's products, points to significant growth for the business.

Nvidia supplies the essential components to build AI data centers. It offers a range of different chips (not just GPUs), networking components, and, most importantly, its CUDA software platform. CUDA is the key piece of Nvidia's moat, enabling customers to tailor the GPU to optimally power a range of tasks, including training large language models.

Nvidia is using this advantage to generate high margins. Last year, revenue grew 65% year over year to $216 billion, and the company converted that revenue into $120 billion in profit.

However, growth is not guaranteed. There are risks, including competition from rival chipmakers. The odds favor Nvidia continuing to maintain its lead, but if growing demand from custom chip suppliers starts to pressure revenue in Nvidia's data center business, that could limit the stock's upside.

Still, Nvidia remains one of the top AI stock holdings for hedge funds, according to The Motley Fool's research. The stock trades at just 22 times this year's earnings and 17 times next year's consensus earnings estimate. If demand remains as strong as Huang suggests and Nvidia continues to deliver, the stock has room to move higher.

Today's Change

(

4.50

%) $

7.10

Current Price

$

164.77

Dell Technologies: The leader in AI servers Growing demand for Nvidia's GPUs means there needs to be server racks to plug them into. This spells more sales for the world's leading server supplier -- Dell Technologies. More orders for Dell's servers could benefit the stock, which trades at a relatively modest 12 times forward earnings.

Dell's business is split between infrastructure solutions (servers, storage, networking) and client solutions (PCs). While the PC side has been sluggish in recent years, the infrastructure segment has been the growth engine. Last year, it surged 40% year over year to $61 billion in revenue.

Huang specifically called out the partnership between Dell and Palantir Technologies during the GTC 2026 keynote address. Nvidia chips power the Dell AI Factory and serve as the backbone Palantir relies on to scale its AI operating system for sovereign and enterprise customers. This collaboration between these companies shows how valuable Dell is to the broader AI ecosystem.

Dell's AI business is exploding, with AI-optimized server revenue up 342% year over year in the fourth quarter, reaching $9 billion. Given this momentum, Dell's valuation leaves room for upside if it continues to execute. Analysts expect earnings to grow at an annualized rate of 15% in the next several years.

Today's Change

(

2.33

%) $

4.78

Current Price

$

210.15

Amazon: The leader in cloud computing Amazon has the look of an unstoppable business. It serves hundreds of millions of customers through its online retail store, but it has also developed fast-growing, high-margin revenue streams in other services such as advertising and cloud computing.

On the AI infrastructure side, the growth engine is Amazon Web Services (AWS), the leading enterprise cloud platform. AWS growth accelerated last year, with revenue up 24% year over year in the fourth quarter.

Importantly, AWS left some revenue on the table during 2025, as demand for AI services exceeded the capacity of its data centers. As Amazon invests in expanding compute capacity, that constraint can ease, potentially supporting stronger growth than investors are pricing in at current share prices.

Huang addressed this opportunity at GTC 2026, saying that OpenAI's recent partnership with AWS could drive "enormous consumption" of cloud computing.

OpenAI recently selected AWS as its exclusive cloud provider for its Frontier enterprise platform, helping companies to build, deploy, and manage AI agents. This could drive sustained usage-based cloud spending, serving as a catalyst for Amazon's growth since AWS generates roughly half of the company's profits.

Analysts expect earnings to grow 18% annually in the coming years. Assuming Amazon performs in line with those estimates, the stock should be a rewarding investment for patient investors. On the basis of its operating cash flow, it is trading at the lowest multiple in over a decade.

Chewy (CHWY +1.07%) is a company your pets surely like, as it sells everything from their favorite foods to toys and other supplies. But investors haven't liked this e-commerce stock much lately, as it's dropped nearly 30% this year.

There isn't one major reason for this, as Chewy has successfully grown its business in recent years and, thanks to a metric I'll talk about in a minute, offers investors a clear view of revenue to come -- and things are looking positive. Sometimes a stock declines because investors are interested in other opportunities at a given moment -- and it isn't a reflection of the stock's prospects. I think this is what we're seeing with Chewy.

Does all of this mean that Chewy may represent a once-in-a-lifetime buying opportunity right now? Let's find out.

Image source: Getty Images.

Chewy's big milestone Chewy has delivered revenue growth in recent years and reached the major milestone of profitability. Initially, the company stuck to the area of e-commerce uniquely in the U.S. But it has expanded the e-commerce business into Canada and, in the U.S., has added veterinary clinics to its repertoire.

CHWY Revenue (Annual) data by YCharts

The vet clinics business is a fantastic idea because it diversifies the revenue stream and, at the same time, offers Chewy the opportunity to bring new customers to its e-commerce business. The clinics are a great way to introduce Chewy to pet parents who haven't yet discovered or tried the e-commerce site.

The power of Autoship Now, here's what I like most about Chewy: More than 80% of the company's total sales come from recurring customers. We know this because the Autoship service makes up that percentage of revenue -- Autoship automatically sends your favorite products to you on a schedule you determine. The idea that regular customers are driving sales is fantastic because it offers us visibility on sales in the coming quarters. It also shows us that customers like Chewy enough to keep coming back.

Today's Change

(

1.07

%) $

0.25

Current Price

$

23.62

As mentioned above, all of this isn't reflected in Chewy's stock performance, and that's left the stock trading at 15x forward earnings estimates, down from more than 30x less than a year ago. This is a very reasonable level considering the points I've mentioned above.

It's impossible to predict exactly when Chewy stock will rebound and advance, but the company has what it takes to climb over the long run: a track record of revenue growth, successful expansion, and recurring customers driving growth. All of this makes Chewy a fantastic stock to buy and hold onto for the long term. And today's valuation means it could be a once-in-a-lifetime buying opportunity right now.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chewy. The Motley Fool has a disclosure policy.

1.74K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Signage for Amazon Web Services (AWS) is displayed at National Retail Federation (NRF) 2026: Retail's Big Show, in New York City, U.S., January 12, 2026. REUTERS/Kylie Cooper Purchase Licensing Rights, opens new tab

SAN FRANCISCO, March 23 (Reuters) - Amazon (AMZN.O), opens new tab said ‌its Amazon Web Services region ​in Bahrain ​has "been disrupted" amid the ⁠current conflict ​in the ​Middle East.

The disruption is due to ​a drone ​activity in the area, ‌an ⁠Amazon spokesperson said, following a Reuters inquiry. ​Amazon ​said ⁠it is helping to ​migrate ​customers ⁠to alternate AWS regions while ⁠it ​recovers.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

Reporting ​by Greg Bensinger; Editing ​by Sonali Paul

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Greg Bensinger joined Reuters as a technology correspondent in 2022 focusing on the world's largest technology companies. He was previously a member of The New York Times editorial board and a technology beat reporter for The Washington Post and The Wall Street Journal. He also worked for Bloomberg News writing about the auto and telecommunications industries. He studied English literature at The University of Virginia and graduate journalism at Columbia University. Greg lives in San Francisco with his wife and two children.

, /PRNewswire/ -- Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) ("K&S" or the "Company"), a global leader in semiconductor assembly solutions and wedge bonding technology, today announced ASTERION™-TW, a new ultrasonic terminal welding system designed to support next generation power module manufacturing. ASTERION™‑TW leverages K&S's longstanding leadership in interconnect innovation, expanding its established ASTERION platform to encompass new ultrasonic, solid-state, terminal welding. This solution provides a flexible, precise, and highly‑capable alternative to mass-reflow for demanding, high-reliability power applications supporting essential markets such as renewable energy, transportation and data center.

ASTERION™ -TW, with its high power and high force capability, enables robust bonding of copper terminals up to 2mm thick. A high-resolution linear motor positioning system provides ±40 microns (3σ) weld placement repeatability, supporting demanding power electronics applications. Designed for manufacturing flexibility, ASTERION™-TW features a ±180° weld head rotation, a 150mm vertical stroke for access into deep cavities, and a 300mm x 300mm work area. An optional material handling system includes an inline pallet conveyor with high force clamping and an integrated cleaning station.

Ultrasonic terminal welding offers compelling enhancements for high‑volume, critical power assembly by enabling a true solid‑state, no‑heat, bonding process. By eliminating external heat, consumables, adhesives, and chemical byproducts this ultrasonic capability enables green manufacturing through lower energy consumption, zero emissions, and improved recyclability of assembled components. Weld force control ensures consistent contact while reducing sensitivity to tolerances, and the inherently precise, low‑waste process provides greater adaptability to evolving power module designs.

"ASTERION™-TW reflects our commitment to deliver high performance interconnect solutions through engineering excellence and close collaboration with our customers," said Ivy Qin, General Manager of Ball & Wedge Bonding at Kulicke & Soffa. "By combining deep process expertise with market-driven innovation, we are dedicated to advancing our customers' capabilities."

As a leader in high-volume wire bonding solutions, K&S offers a comprehensive power interconnect portfolio. From the AVALINE™ clip attach solutions, to the growing ASTERION portfolio which now spans wire and ribbon wedge bonding with ASTERION, pin welding with ASTERION™‑PW, and now terminal welding with ASTERION™‑TW, these solutions reflect K&S's strategy to extend interconnect offerings while building on decades of ball and wedge bonding leadership and process expertise.

Visit K&S at SEMICON China 2026

Together with a broad portfolio of K&S solutions, ASTERION™-TW will debut at the SEMICON China Trade Show – Hall N3, Booth #3431 – in Shanghai, from March 25, 2026 through March 27, 2026. Please contact your regional K&S sales team for additional information.

For more information, visit www.kns.com. 

About Kulicke & Soffa

Kulicke & Soffa is a global leader in semiconductor assembly technology, advancing device performance across automotive, compute, industrial, memory and communications markets. Founded on innovation in 1951, K&S is uniquely positioned to overcome increasingly dynamic process challenges – creating and delivering long-term value by aligning technology with opportunity.

Contacts:

Kulicke & Soffa
Marilyn Sim
Public Relations
P: +65-6880-9309
[email protected]

Kulicke & Soffa
Joseph Elgindy
Finance
P: +1-215-784-7500
[email protected]

SOURCE Kulicke & Soffa Industries, Inc.

The logo of Australian oil and gas exploration and production company Santos is displayed during the LNG 2023 energy trade show in Vancouver, British Columbia, Canada, July 12, 2023.... Purchase Licensing Rights, opens new tab Read more

SummaryCompaniesShutdown linked to equipment replacement at offshore vesselHalts exports from Barossa projectOutage following export disruptions amidst Middle East conflictMarch 24 (Reuters) - Australia's Santos (STO.AX), opens new tab said on Tuesday it has temporarily ‌shut its Darwin liquefied natural gas plant, interrupting exports from a newly restarted supply chain at a time when markets are tightening due to disruptions from the Middle East.

The outage comes as LNG ​exports to Europe and Asia are already under pressure following disruptions ​to shipments from Qatar, after a series of Iran-linked attacks on ⁠Gulf energy infrastructure in response to Israeli strikes earlier this month.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

Australia ​is one of the world's largest LNG exporters and a critical supplier to ​Asian buyers.

Santos, the country's No. 2 oil and gas producer, said the shutdown was linked to equipment replacement work on the BW Opal floating production vessel at the offshore Barossa gas and ​condensate project, which feeds the Darwin plant.

A company spokesperson said the shutdown ​was planned and related to commissioning activities, but did not specify how long the ‌plant ⁠would remain offline.

However, an email from Santos to stakeholders suggested it could take "a number of weeks" for Darwin LNG to resume operations, a timeframe reported by the Australian Financial Review.

"We are in the final stages of commissioning for ​Barossa LNG to ​flush the system ⁠before coming back on and getting back to full rates," the spokesperson said.

Darwin LNG had resumed exports earlier this year ​after Barossa's delayed start-up, which had faced technical issues, including compressor seal problems ​that affected ⁠production stability.

In its quarterly production report, Santos said it expected total production between 101 million and 111 million barrels of oil equivalent (mmboe) for 2026, with Barossa expected ⁠to ​contribute around 19 mmboe.

Santos operates Barossa with ​a 50% stake, alongside South Korea's SK E&S, which holds 37.5%, and Japan's JERA with 12.5%.

Reporting ​by Nikita Maria Jino in Bengaluru; Editing by Mrigank Dhaniwala and Eileen Soreng

Our Standards: The Thomson Reuters Trust Principles., opens new tab

38 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Readers are advised to fact-check thoroughly before making any investment-related decisions; this reflects the personal views of the author and should not be pursued as formal financial or investment advice in any manner. While every effort has been made to ensure accuracy, errors may exist in the data and financial projections presented. The author is not responsible for any financial gains or losses incurred from investments made based on this content. For any additional information regarding the company or any clarification, feel free to comment. Happy to discuss anything further with regard to the presented investment thesis.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

TRON DAO, the community-governed organization behind one of the most heavily used blockchain networks for stablecoin settlement, is scaling its AI Fund from $100 million to $1 billion as it doubles down on building infrastructure for the burgeoning agentic economy, according to a Monday announcement.

The fund targets early-stage investments and acquisitions across key areas such as agent identity, stablecoin payments, tokenized assets, and developer tools for autonomous financial systems.

The initiative expands on a 2023 thesis that anticipated the convergence of AI and blockchain.

With that convergence now gaining validation, TRON is positioning AI agents as independent economic actors that require fully onchain systems combining identity, payments, and ownership.

Onchain AI agents have scaled to process millions in payments, but their activity remains a very small portion of overall stablecoin volumes each year. Analyst projections suggest the agentic economy could reach $30 trillion by 2030.

Fee economics and AI agents Multiple blockchain networks, including Ethereum, Solana, and Base, are actively developing use cases around automated and high-frequency transaction systems, each with varying levels of infrastructure maturity and funding.

TRON’s competitive position is largely driven by transaction cost efficiency. For applications that rely on large volumes of small transactions, the fee structure becomes a critical constraint, favoring networks optimized for low-cost settlement.

New technical standards The expansion comes as new technical standards develop across the ecosystem, including ERC-8004, an identity protocol for autonomous agents that launched earlier this year and surpassed 24,000 identity NFT registrations in its first month, as well as the x402 protocol, which is designed to facilitate machine-to-machine payments and is starting to see early developer adoption.

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.

Breaking Signal·Market Impact: High

Artificial Superintelligence Alliance (FET) jumped 13.20% to $0.2376 on March 24, topping the gainers list as mid-caps outperformed, according to CoinGecko data. Siren (SIREN) fell 58.85% to $1.02 to lead decliners. LayerZero (ZRO), Aptos (APT), and Bittensor (TAO) also pushed higher, while Ethena (ENA), Kaspa (KAS), Pi Network (PI), and Hyperliquid (HYPE) eased.

Top Gainers Artificial Superintelligence Alliance (FET) rose 13.20% to $0.2376, bringing its market capitalization to $537.09M. The alliance groups Fetch.ai, SingularityNET, and Ocean Protocol under a coordinated AI effort that has included plans for token consolidation across the stack. The theme puts FET in the thick of on-chain AI infrastructure narratives, now alongside higher-cap peer Bittensor on today’s board. Liquidity concentration across the alliance’s assets remains a key watch as integrations progress.

A7A5 (A7A5) gained 12.58% to $0.0135, taking its market cap to $527.67M. No specific news has been tied to the move. The token’s climb placed it second among large mid-caps by percentage change over 24 hours, with price discovery unfolding above the cent level.

Aptos (APT) advanced 11.52% to $1.05, with a market value of $836.86M. The Layer 1 network is built around the Move language and parallel execution, with aims at high throughput and quick finality. Backed by a roster of venture investors since launch, Aptos continues to court DeFi, gaming, and payments builders as it competes in the L1 field.

LayerZero (ZRO) climbed 11.41% to $2.19, lifting its market cap to $552.28M. The protocol underpins cross-chain messaging and bridging for applications that need to route assets or data across networks. Traders pointed to broader altcoin rotation. Adoption of omnichain primitives often tracks liquidity cycles across EVM and non-EVM chains, a backdrop ZRO has tended to trade with.

Bittensor (TAO) added 10.85% to $301.47, bringing its market capitalization to $2.90B. The network coordinates machine learning subnets that compete for emissions, rewarding models and routing useful outputs via a peer-to-peer incentives layer. TAO has become a bellwether for AI-linked on-chain compute narratives, and its triple-digit token price keeps it among the priciest names by unit cost. The day’s double-digit gain puts TAO alongside FET at the front of the AI basket.

Top Losers Siren (SIREN) slid 58.85% to $1.02, with market capitalization at $743.01M. The magnitude of the drawdown dominated the losers board and eclipsed declines in larger caps. Details were sparse at press time, with no immediately visible catalyst accompanying the drop. Price action remains volatile around the $1 handle after the steep move.

Ethena (ENA) fell 4.72% to $0.0922, setting market cap at $783.04M. Ethena is the issuer behind the delta-hedged synthetic dollar USDe, which targets dollar stability using hedged basis positions across venues. ENA governs protocol incentives and risk parameters. The token’s modest decline contrasted with more severe selling among smaller names on the day.

Kaspa (KAS) eased 4.58% to $0.0346, giving the proof-of-work blockDAG project a $944.95M market cap. Kaspa’s design emphasizes rapid block times and high throughput using a DAG-based consensus rather than a linear chain. The pullback keeps KAS near the billion-dollar threshold by valuation, a line it has tested during prior swings.

Pi Network (PI) dipped 2.85% to $0.1887, with a market value of $1.85B. Pi promotes mobile mining and a large user base, with token transfers historically limited as the project phased toward broader mainnet access. The token’s valuation remains sizable even after today’s move. Price formation has often been fragmented across venues that support PI pairs.

Hyperliquid (HYPE) declined 1.71% to $37.50, setting market cap at $8.94B. The onchain perpetuals exchange operates an appchain architecture and has drawn significant derivatives volume. HYPE’s modest slip came after outsized gains in prior sessions across onchain perp venues. Liquidity in the venue’s flagship markets remains a focal point for traders watching fee flows and emissions.

Market Outlook The day’s tape split sharply: the top gainer rose 13.20% while the biggest loser shed 58.85%. AI-linked names featured on the upside with FET and TAO, while infrastructure tokens like ZRO and L1 coin APT also printed double-digit gains. On the downside, SIREN’s collapse overshadowed milder dips in ENA, KAS, PI, and HYPE.

Into the week, watch whether AI narratives hold bid after FET’s 13.20% jump and if TAO can extend above $301.47. Positioning around cross-chain activity may keep ZRO in focus, while unlock schedules, listings, or roadmap updates across these names could skew flows. Broader direction from Bitcoin will remain the key signal for whether mid-caps sustain this rotation.

SourcesCoinGecko

This article was written with AI assistance and reviewed by the The Currency analytics editorial team. Information presented is sourced from publicly available reports. The Currency analytics strives for accuracy but cannot guarantee completeness. This article does not constitute financial advice.

Post Views: 2

Ethereum (ETH) is still generating more fee revenue than Solana (SOL) on a headline basis, but the more consequential story for 2026 is shifting beneath the surface: on-chain profitability is increasingly determined not by where fees are paid, but by which network structure is able to ‘absorb’ and retain them.

As of March 24 (UTC), Ethereum recorded $9.66 million in 24-hour fees, down 7.08% from the prior day, while Solana logged $4.38 million, up 4.98%. Ethereum’s total remains roughly 2.2 times larger, yet analysts say the ‘quality of revenue’—how sustainably it is captured and by whom—is being rapidly re-mapped as Layer 2 (L2) adoption accelerates and stablecoin and real-world asset (RWA) flows reorganize liquidity across chains.

The most visible inflection point is Ethereum’s rollup-driven scaling model. Even as activity across the broader Ethereum ecosystem rises, a growing share of transactions are migrating off the base chain and onto L2 networks such as Arbitrum and Optimism. That shift doesn’t necessarily signal weakening demand; instead, it reflects a structural relocation of execution to cheaper environments, compressing the amount of fees recognized at the ‘base layer’ itself.

Ethereum’s average transaction fee hovering around $0.21 illustrates the dynamic. The network continues to serve as the settlement and security anchor for a large portion of decentralized finance (DeFi) and tokenized asset issuance, but the fee stream is increasingly distributed across modular components—execution on rollups, data availability and settlement on L1, and value capture split among sequencers, bridges, and application layers. Market observers often describe this as revenue ‘leakage’: value creation persists, while fee recognition becomes fragmented.

Solana, by contrast, is pursuing the opposite route, keeping more activity within a single, high-throughput environment. Its core pitch—fast execution and low costs on one layer—has been translating into a fee trajectory that can rise alongside usage, rather than being structurally offloaded to auxiliary networks. The recent increase in daily fee totals, even from a lower base than Ethereum’s, is being read by some traders as evidence that Solana is consolidating fee capture as it scales.

The competition is increasingly being shaped by stablecoin settlement and RWA-related activity—two areas that can generate persistent transaction flow and anchor liquidity. Market participants are watching how USD Coin (USDC) circulation, exchange liquidity, and tokenized asset issuance migrate between ecosystems, because those flows can effectively determine which chains and applications become ‘default rails’ for recurring transfers.

In that context, the fee contest is less about raw totals on any single day and more about the durability of each network’s revenue architecture. Ethereum’s modular approach may optimize user costs and throughput across L2s, but it forces the ecosystem to continuously balance scalability with cohesive value capture at the base layer. Solana’s integrated approach may concentrate fee revenue more directly, but it also ties scaling performance and fee capture to a single environment’s ability to sustain growth.

For the broader market, the emerging takeaway is that 2026’s on-chain winners may not be decided purely by transaction counts or headline fees, but by the networks that best convert structural demand—RWA settlement, stablecoin transfers, and application-layer usage—into predictable, retained fee streams. That shift is likely to influence how investors evaluate ‘cash-flow-like’ fundamentals in crypto networks, particularly as institutional attention gravitates toward measurable, recurring on-chain activity.

Article Summary by TokenPost.ai

🔎 Market Interpretation

Headline fees still favor Ethereum, but the competitive battleground is shifting: Ethereum posted $9.66M in 24h fees vs Solana’s $4.38M (ETH ~2.2× SOL). However, analysts increasingly focus on revenue retention—who ultimately captures fees as usage scales—rather than raw totals.

Ethereum’s “modular” scaling changes where fees show up: As activity migrates to L2s (e.g., Arbitrum, Optimism), Ethereum L1 remains a settlement/security hub, but L1 fee recognition is compressed even if ecosystem activity grows.

Revenue fragmentation becomes a core metric for ETH: With average transaction fees around $0.21, value capture is increasingly split across rollup execution, L1 settlement/data availability, sequencers, bridges, and apps—often described as fee “leakage” from the base layer.

Solana’s “integrated” model supports consolidated fee capture: By keeping execution on one high-throughput layer, Solana can see fees rise more directly with usage, which some traders interpret as improving monetization as activity scales.

Stablecoins and RWAs are emerging as decisive demand sources: Market attention is moving toward which chain becomes the default rail for recurring flows like USDC settlement and tokenized asset issuance, because these can drive persistent transactions and defensible liquidity.

2026 valuation lens: “cash-flow-like” on-chain fundamentals: Investors may increasingly rank networks by their ability to convert structural demand (stablecoins, RWAs, app usage) into predictable, retained fee streams, especially as institutional evaluation emphasizes measurable recurring activity.

💡 Strategic Points

For investors analyzing ETH vs SOL: Track not only fee totals, but fee capture path—what share accrues to L1 validators/burn vs L2 sequencers vs application-level rent extraction.

Ethereum monitoring checklist:

L2 share of transactions vs L1 (signals continued execution offload).

Rollup economics: sequencer revenue, proof costs, and how upgrades affect fee distribution.

Data availability & settlement demand on L1 (whether L2 growth still translates into L1 demand).

Bridge and interoperability costs (friction can influence where liquidity and users remain).

Solana monitoring checklist:

Fee growth vs usage growth (tests whether monetization scales without harming UX).

Network performance resilience under load (integrated model concentrates execution risk).

Stablecoin liquidity depth and market-maker participation (helps determine “default rail” status).

Stablecoin/RWA “rail competition” implication: Chains that win recurring settlement flows may gain a more durable revenue base than chains optimized primarily for episodic speculative activity.

Portfolio/risk framing: Ethereum’s model can improve user costs and throughput but may dilute base-layer monetization; Solana’s model can concentrate monetization but increases dependence on a single execution environment’s sustained performance.

What could change the thesis: Major shifts in L2 fee-sharing mechanisms, L1 pricing dynamics for data availability, or large-scale institutional RWA issuance choosing one ecosystem as primary settlement.

📘 Glossary

L1 (Layer 1): The base blockchain (e.g., Ethereum mainnet, Solana) that provides core security and final settlement.

L2 (Layer 2): Scaling networks that execute transactions off the L1 and post proofs/data back to it (e.g., optimistic and zk rollups).

Rollup: An L2 design that batches many transactions and settles them on L1, typically reducing user fees.

Sequencer: The entity that orders and submits L2 transactions/batches; often a primary collector of L2 fees.

Settlement: Final confirmation of transactions, typically anchored on L1 for security assurances.

Data Availability (DA): Ensuring transaction data is accessible so the network can verify and reconstruct state; DA costs can drive L1 demand even when execution moves to L2.

Fee “Leakage” (fragmentation): When economic value generated in an ecosystem is captured by multiple layers (L2s, bridges, apps) rather than accruing mainly to the base chain.

Stablecoin settlement: Repeated transfers/clearing of stablecoins (e.g., USDC) that can create consistent on-chain transaction flow.

RWA (Real-World Assets): Tokenized representations of off-chain assets (e.g., bonds, funds, invoices) that can drive recurring issuance/redemption and settlement activity.

“Cash-flow-like” fundamentals: Using recurring fees/revenues as a proxy for sustainable economic value, analogous to cash flows in traditional markets.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Bitcoin price started a recovery wave from $68,000. BTC is now back above $70,000 and might struggle to continue higher in the near term.

Bitcoin started a decent recovery wave above $69,500 and $70,000. The price is trading above $70,000 and the 100 hourly simple moving average. There was a break above a bearish trend line with resistance at $69,500 on the hourly chart of the BTC/USD pair (data feed from Kraken). The pair might start another decline if it stays below the $71,500 and $72,000 levels. Bitcoin Price Attempts Recovery Bitcoin price found support near the $67,500 zone and recently started a recovery wave. BTC climbed above the $68,800 and $69,500 resistance levels.

There was a break above a bearish trend line with resistance at $69,500 on the hourly chart of the BTC/USD pair. The bulls were able to push the price above the 38.2% Fib retracement level of the downward move from the $75,999 swing high to the $67,343 low.

However, the price faced resistance near the $71,500 zone and the 50% Fib retracement level of the downward move from the $75,999 swing high to the $67,343 low. Bitcoin is now trading above $70,000 and the 100 hourly simple moving average.

If the price remains stable above $70,000, it could attempt a fresh increase. Immediate resistance is near the $71,650 level. The first key resistance is near the $72,000 level. A close above the $72,000 resistance might send the price further higher.

Source: BTCUSD on TradingView.com In the stated case, the price could rise and test the $73,500 resistance. Any more gains might send the price toward the $74,200 level. The next barrier for the bulls could be $75,000.

Another Decline In BTC? If Bitcoin fails to rise above the $71,650 resistance zone, it could start another decline. Immediate support is near the $70,000 level. The first major support is near the $69,350 level.

The next support is now near the $68,950 zone. Any more losses might send the price toward the $68,000 support in the near term. The main support now sits at $67,500, below which BTC might struggle to recover in the near term.

Technical indicators:

Hourly MACD – The MACD is now losing pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $68,950, followed by $68,000.

Major Resistance Levels – $71,650 and $72,000.

NFT sales rebounded over the past week, but the recovery came with a clear caveat: fewer transactions and a growing concentration in high-value deals—particularly on Bitcoin (BTC) and BRC-20-linked NFTs—suggesting the market’s upside is being driven by ‘whales’ rather than broad-based retail activity.

According to data from NFT analytics platform CryptoSlam, weekly NFT sales reached $39.48 million as of March 16 (UTC), up 24% from the prior week. The number of buyers climbed to 173,900 (+78%) and sellers rose to 171,400 (+76%), while total transactions fell to 739,100, down 31% week over week.

The divergence—more participants but fewer sales—points to rising average ticket sizes and a market structure increasingly dominated by large, infrequent purchases. In practical terms, activity is expanding, but liquidity appears to be concentrating into a smaller number of high-value trades instead of a broad rise in low-to-mid priced collecting.

By blockchain, Bitcoin led weekly NFT sales volume, posting $11.85 million—up 57%—with 8,436 buyers (+54%). Ethereum (ETH) ranked second at $7.62 million, down 18% on the week, even as its buyer count rose to 5,357 (+65%). Polygon (POL) came in third with $5.71 million in sales, a surge of 581%, alongside 5,631 buyers (+73%).

Elsewhere, Base recorded $5.05 million in volume (+31%) with 37,993 buyers (+14%). BNB Chain posted $3.13 million (–30%) with 16,766 buyers (+51%). Immutable logged $2.62 million (+9%) with 4,193 buyers (+64%), while Flow reached $971,800 (+18%) with 5,664 buyers (+38%). Blast reported $580,200 in weekly volume, with an extreme percentage jump from a minimal prior base; however, buyer counts were listed as zero, underscoring how thin or irregular the underlying activity may be.

At the collection level, ‘$X@AI BRC-20 NFTs’ was the top-selling series of the week, generating $6.81 million in volume—up 1,101% week over week. ‘Courtyard’ placed second with $4.97 million (flat on the week), and ‘Flying Tulip PUT’ ranked third at $3.92 million (+52%). Additional notable collections included ‘0xbb5ec6fd4b61723bd45c399840f1d868840ca16f’ with $3.00 million (+44%) and ‘Guild of Guardians Heroes’ at $1.38 million (+14%).

The week’s market concentration was most visible in the top individual sale. CryptoSlam data shows ‘$X@AI BRC-20 NFTs #b51707…55c9i0’ sold for $5.87 million, priced at 83.8816 BTC. The next-largest trade—‘$X@AI BRC-20 NFTs #78407b…bf9bi0’—fetched $935,241 (13.358 BTC). Several ‘$QCLAW BRC-20 NFTs’ pieces followed, each selling around $140,027 (2 BTC), reinforcing the role of Bitcoin-denominated pricing in shaping headline成交 values.

Marketplace data also suggested that the rebound in total sales did not translate into uniformly stronger platform activity. DappRadar ranked OpenSea, Courtyard, and Blur as the top NFT marketplaces by weekly volume. OpenSea posted $9.82 million in volume, down 10% from the prior week. Courtyard recorded $5.53 million (–55%), while Blur logged $1.34 million (–29%), indicating that major venues saw shrinking volumes despite the broader rise in headline sales.

Overall, the latest weekly snapshot points to a market in transition: participation is rising, but the decline in transaction count and the dominance of a handful of large Bitcoin-based NFT trades suggest a ‘top-heavy’ recovery. If this pattern persists, near-term performance may remain sensitive to a small number of high-value buyers and to continued momentum in Bitcoin-native NFT ecosystems such as BRC-20.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

On-chain data shows the Bitcoin long-term holders have seen their supply go up recently, despite the unconvincing price action in the cryptocurrency.

Bitcoin Long-Term Holder Supply Has Surged By 332,000 Over The Past Month As pointed out by CryptoQuant community analyst Maartunn in an X post, the Bitcoin long-term holder supply has been following an uptrend recently. The “long-term holders” (LTHs) refer to the BTC investors who have been holding onto their coins for more than 155 days.

The LTHs make up for one of the two main divisions of the BTC market done on the basis of holding time; the other side, containing coins aged 155 days or less, is called the “short-term holders” (STHs).

Statistically, the longer an investor keeps their coins dormant, the less likely they become to sell them in the future. As such, the STHs with their low holding time can be considered to include the weak hands of the market, while the LTHs can represent the stalwart diamonds.

Now, here is the chart shared by Maartunn that shows the recent 30-day net position change trend in the supply of these two Bitcoin groups:

Looks like the LTHs have seen their supply go up in recent months | Source: @JA_Maartun on X As is visible in the above graph, the Bitcoin LTHs saw a negative monthly supply change during the second half of 2025, implying members of the cohort were breaking their dormancy, potentially to participate in selling.

From the chart, it’s apparent that the selloff was the most intense during November, suggesting even the diamond hands of the network were reacting to the crash. The metric remained negative for the rest of the year, but in 2026, a shift has occurred; the LTH netflow has been positive since January and its value has only been climbing over time. Currently, it’s sitting at +332,600 BTC.

Something to keep in mind is that while declines in the LTH supply can reflect distribution, the reverse isn’t true. This is because coins only become part of the LTH group after they have been held for a period of over 155 days. Thus, an increase in the LTH supply doesn’t mean that accumulation is happening in the present, but rather that it took place five months ago. Selling has no such delay attached as tokens see their age instantly reset back to zero as soon as they are involved in a network transaction.

Nonetheless, a rise in the LTH supply is naturally still a useful signal, reflecting an increased tolerance for long-term holding among investors. Interestingly, the recent large 30-day inflow into the group has come while the market has gone through uncertainty owing to the war. As such, it would appear that a segment of the investors continue to believe in Bitcoin even in these circumstances.

BTC Price At the time of writing, Bitcoin is trading around $68,500, down more than 6% in the last week.

The price of the coin seems to have been sliding down over the last few days | Source: BTCUSDT on TradingView Featured image from Dall-E, chart from TradingView.com

Ethereum price started a recovery wave from the $2,025 zone. ETH is now consolidating above $2,120 and might struggle to clear the $2,200 resistance.

Ethereum started a recovery wave above the $2,120 zone. The price is trading above $2,120 and the 100-hourly Simple Moving Average. There is still a key bearish trend line active with resistance at $2,165 on the hourly chart of ETH/USD (data feed via Kraken). The pair could start a fresh decline if it stays below the $2,165 resistance. Ethereum Price Faces Resistance Ethereum price managed to stay above $2,000 and started a recovery wave, like Bitcoin. ETH price was able to climb above the $2,080 and $2,120 resistance levels.

The price cleared the 38.2% Fib retracement level of the downward move from the $2,385 swing high to the $2,025 low. More importantly, there was a break above one of the two bearish trend lines with resistance at $2,120 on the hourly chart of ETH/USD.

Ethereum price is now trading above $2,100 and the 100-hourly Simple Moving Average. However, the bears are active near $2,180. Besides, there is still a key bearish trend line active with resistance at $2,165.

If the bulls remain in action above $2,065, the price could attempt another increase. Immediate resistance is seen near the $2,165 level. The first key resistance is near the $2,200 level. The next major resistance is near the $2,250 level. A clear move above the $2,250 resistance might send the price toward the $2,300 resistance or the 76.4% Fib retracement level of the downward move from the $2,385 swing high to the $2,025 low.

Source: ETHUSD on TradingView.com An upside break above the $2,300 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $2,350 resistance zone or even $2,400 in the near term.

Another Decline In ETH? If Ethereum fails to clear the $2,165 resistance, it could start a fresh decline. Initial support on the downside is near the $2,120 level. The first major support sits near the $2,065 zone.

A clear move below the $2,065 support might push the price toward the $2,025 support. Any more losses might send the price toward the $2,000 region. The main support could be $1,940.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now above the 50 zone.

Major Support Level – $2,065

Major Resistance Level – $2,165

Ethereum (ETH) is trading at $2,135, 9% below its March peak, as a post-rally distribution phase plays out on the daily chart.

Two on-chain signals point in opposite directions — whale wallets were selling into the peak, but a sharp exchange supply withdrawal now suggests buyers are stepping in at current levels.

Ethereum Whale Wallets Distributed Into the March Rally PeakSantiment data tracking wallets holding between 100,000 and 1,000,000 ETH shows large holders increased their balances steadily through mid-March as the price climbed toward $2,370. That buying helped power the 21.44% recovery rally from the March 9 low near $1,950.

The turning point came around March 21. As the price peaked, whale wallet balances dropped sharply alongside Ethereum’s price, declining from approximately $2,332 to $2,053 in two days.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Ethereum Whale Holdings. Source: SantimentThe simultaneous fall in both whale balance and price confirms these large holders were distributing — not buying — into the rally’s upper range.

This distribution is the direct cause of the 13% correction annotated on the price chart. The selling was not a panic liquidation; it was a deliberate exit by large wallets at elevated prices.

Buying ETH Is Still The Dominant SentimentDespite the whale-driven selloff, exchange supply data reveals a powerful counter-move. Between March 21 and 22, approximately 870,000 ETH was withdrawn from all exchanges — dropping total exchange supply from roughly 8.12 million to 7.29 million ETH.

This represents approximately $1.8 billion in ETH moved off exchanges. Coins leaving exchanges signal buying intent — holders withdrawing to self-custody are not planning to sell immediately.

Ethereum Exchange Balance. Source: SantimentThis divergence is the crux of the near-term case. Whale wallets sold; a separate cohort of buyers simultaneously pulled $1.43 billion off exchanges. The net effect on price depends on which force dominates over the coming days.

ETH Price Areas To WatchEthereum price is just above the Fibonacci 0.786 retracement at $2,027. This level has provided support on two prior tests and is the last meaningful floor before $1,928. A daily close above $2,148 would provide ETH with much-needed support

ETH Price Analysis. Source: TradingViewAdding weight to the case for a floor, Net Realized Profit/Loss data from Glassnode shows the single largest positive reading of the entire period on March 23, approximately +$380 million. After six weeks of predominantly red bars, this spike means buyers are now realizing profits.

Ethereum Net Realized Profit/Loss. Source: GlassnodeTo reverse the correction, ETH needs a daily close above $2,148. This would enable ETH to pursue recovery of the recent 13% correction towards $2,350. The $1.43 billion exchange withdrawal provides the raw buying material for that move. Whether it arrives this week depends on whether the $2,027 Fibonacci floor holds on any further test.

On the other hand, if this buying were to turn into selling soon, the Ethereum price could end up losing the support of $2,027. This would push the altcoin king towards the next major support of $1,928, losing which will invalidate the bullish thesis.